|Day Low/High||0.23 / 0.23|
|52 Wk Low/High||0.17 / 0.35|
Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. But investigators at MD Anderson and the two other hospitals conducting the DCVax-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.
These under-$10 stocks look ready to break out and trade higher from current levels.
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail means for biotech investor sentiment, but I'll leave the interpretations up to you.
On Wednesday afternoon during a presentation at an investor conference, Northwest Bio CEO Linda Powers once again offered conflicting language on the timeline for enrollment of 312 glioblastoma patients in the phase III study of the experimental cancer vaccine DC-Vax.
I'm sure Northwest Bio thought it would raise its profile with a booth the size of a small Illinois town, but from an investors' perspective, the company was simply the brunt of guffaws over the weekend for wasting a ridiculous amount of money.
A fool and is money are soon parted, the old idiom goes. I'll add this: The money parting often happens faster to fools who invest in sketchy small-cap biotech stocks.
Cramer says he was too late on Tata Motors but prefers Williams-Sonoma over Abercrombie & Fitch.
Why it is that when interest rates fell again today, the markets automatically assumed the economy is slowing? Cramer wonders.
Investors in Northwest Biotherapeutics Inc saw new options begin trading this week, for the January 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The tumor response rate attributable to Northwest Biotherapeutics DCVax-Direct is zero. None of the 19 patients with advanced, metastatic cancers have responded to treatment with DCVax-Direct in an ongoing phase I clinical study.
It's been five months since Northwest Biotherapeutics told investors that independent monitors were conducting an interim efficacy analysis of the phase III study of DC-Vax in patients with newly diagnosed glioblastoma multiforme (GBM.)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
An explanation of Northwest Bio's "up to" $32 million financing deal.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Northwest Bio is now acknowledging that no agreement with the FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.
Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a skilled dissembler, so her update, while amazingly negative for DC-Vax, was spun positive. It was an award-winning performance.
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
Northwest Bio: A German Translation Ate My DCVax Press Release
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
Investors in Northwest Biotherapeutics Inc saw new options begin trading this week, for the October 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
These stocks look ready to break out and trade higher from current levels.
Handicapping the potential of Galena Biopharma, CytRx and Northwest Biotherapeutics requires a solid understanding of what has been driving share prices.
Investors in Northwest Biotherapeutics Inc saw new options begin trading this week, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.